
BIOGRAPHICAL SKETCH

NAME: Ekaterine Dolmazashvili, MD, PhD, MPH

POSITION TITLE: Infectious diseases specialist

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Ivane Javakhishvili Tbilisi State University	MD	1998-2004	Faculty of Medicine
Ivane Javakhishvili Tbilisi State University	MPH	2004-2006	Faculty of Medicine, <i>Master</i>
Tbilisi State Medical University	ID specialist	2005-2008	<i>Program: Public Health</i> Infectious Diseases
Ivane Javakhishvili Tbilisi State University	PhD	2015-2017	Medicine

Positions and Honors

Positions and Employment

2005-2008	Junior physician at Infectious Diseases, AIDS and Clinical Immunology Research Center Tbilisi, Georgia
2007-2008	Junior physician at Hepatology Clinic HEPA Tbilisi, Georgia
2008-present	ID specialist at Infectious Diseases, AIDS and Clinical Immunology Research Center Tbilisi, Georgia
2008-present	ID specialist at Hepatology Clinic HEPA Tbilisi, Georgia
2008-2017	Assistant at Ivane Javakhishvili Tbilisi State University, Faculty of Medicine, Tbilisi, Georgia
2018-present	Assistant Professor at European University
2018-present	Invited lecturer at Batumi Shota Rustaveli State University, Faculty of Natural Sciences and Health Care

Publications:

1. Analysis of Factors of Risk of Spontaneous Abortions with the Purpose of Carrying out Periconceptional Prophylaxis; **Dolmazashvili E.**; Karseladze R. Georgian Medical News No 7, 8 [100,101]), July–August 2003 pp.: 67-70
2. Herpes zoster in patients of different age groups; Sharvadze L., Tsertsvadze T., Gochitashvili N., Stvilia K., **Dolmazashvili E.** Sakartvelos Samedicino Moambe; January-March 2006; pp: 110-116
3. HIV prevalence among high risk behavior group persons with herpes zoster infection. Sharvadze L., Tsertsvadze T., Gochitashvili N., Stvilia K., **Dolmazashvili E.** Georgian Medical News No 3 [132]) March 2006; pp.: 60-64
4. IFN/RBV treatment induced anemia and its correction with epoetin alfa in patients with hepatitis C. Sharvadze L., Tsertsvadze T., Gochitashvili N., Kakabadze T., **Dolmazashvili E.** Georgian Medical News No 8 [137] August 2006; pp.: 62-65
5. Peculiarities of herpes zoster in immunocompetent and immunocompromised hosts; Sharvadze L., Tsertsvadze T., Gochitashvili N., Bolokadze N., **Dolmazashvili E.** Georgian Medical News No 12 [141] December 2006; pp.: 50-53
6. Acute/recent HCV infection. Clinical laboratory variants. Host and viral characteristics. Tsertsvadze T., Sharvadze L., Dzigua L.; **Dolmazashvili E.**; Nelson K. Georgian Medical News No 12 (165) December 2008; pp.: 43-49

7. Assessment of liver fibrosis and cirrhosis by Transient Elastography among patients with chronic HBV and HCV infection in Georgia; Tsertsvadze T., **Dolmazashvili E.**, Abutidze A., Sharvadze L., Karchava M. Georgian Medical News No 12 (165) December 2008; pp.: 38-43
8. Fibroscan and Fibrotest/Fibromax to assess liver fibrosis/cirrhosis in patients with chronic HBV and HCV infection in Georgia; **Dolmazashvili E.**; Zhamutashvili M.; Svanidze M.; Nizharadze N. Abutidze A. Georgian Medical News No 12 (165) December 2008; pp.: 83-87
9. Dermatological manifestations in HIV/AIDS patients; Sharvadze L., **Dolmazashvili E.**, Bolokadze N., Rukhadze N., Tsertsvadze T. South Caucasian Dermatology and Venereology News, Issue #1(6), January-December, 2008
10. Mucous membrane diseases in HIV/AIDS patients; Bolokadze N., Sharvadze L., **Dolmazashvili E.**, Abutidze A., Tsertsvadze T. South Caucasian Dermatology and Venereology News, Issue #1(6), January-December, 2008
11. IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. Karchava M.; Sharvadze L.; Chkhartishvili N.; Kenrad N.; Gochitashvili N.; Gatserelia L.; Dvali N.; **Dolmazashvili E.**; Dzigua L.; Badridze N.; Zhamutashvili M.; Tsertsvadze T. Eur J Gastroenterol Hepatol 2012 Jul;24(7):817-23
12. Occurrence of occult HCV infection among HIV infected patients in Georgia. Gatserelia L, Sharvadze L, Karchava M, **Dolmazashvili E**, Tsertsvadze T. Georgian Med News. 2014 Jan ;(226):37-41.
13. Discrepancy between HCV Structural and Nonstructural Genes in Georgian Genotype Two Patients. Tsertsvadze T, Karchava M, Sharvadze L, Gatserelia L, **Dolmazashvili E**. *Georgian Med News* 2014 Oct;(235):74-8.
14. High Incidence of the Hepatitis C Virus Recombinant 2k/1b in Georgia: Recommendations for Testing and Treatment. Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, **Dolmazashvili E**, Norder H, Tsertsvadze T. [Hepatology Research](#) 45(13) · February 2015
15. Impact of hepatitis C virus recombinant form RF1_2k/1b on HCV treatment outcomes within Georgian national hepatitis C elimination program. Karchava M, Chkhartishvili N, Sharvadze L, Abutidze A, Dvali N, Gatserelia L, Dzigua L, Bolokadze N, **Dolmazashvili E**, Kotorashvili A, Imnadze P, Gamkrelidze A, Tsertsvadze T. Hepatol Res. 2017 Mar 4. doi: 10.1111/hepr.12890
16. Regression of liver fibrosis over a 24-week period after completing direct acting antiviral (DAA) therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: Results of hepatology clinic HEPA experience
Dolmazashvili E., Abutidze A., Chkhartishvili N., Karchava M., Sharvadze L., Tsertsvadze T. *European Journal of Gastroenterology and Hepatology*, accepted 27 June 2017.
17. Comparative study of FIB-4 index and transient elastography among patients with chronic hepatitis C virus infection in Georgia. **Dolmazashvili E.**, Karchava M., Abutidze A., Sharvadze L., Tsertsvadze T. *Georgian Med News* 2017 March ;(264):81-6.

Guideline

Treatment and care of HIV/AIDS patients, National guideline, version 4, 2009

Presentations

- Butsashvili M., Kamkamidze G., Metreveli D., Gvinjilia L., Kuchuloria T., Gamkrelidze A., Zakalashvili M., **Dolmazashvili E.**, Kerashvili V., Nasrullah M., Averhoff F.
Improvement in liver fibrosis among patients with hepatitis C who achieved sustained viral response after direct acting antivirals treatment, in country of Georgia, The International Liver Congress, 10-14 April 2019, Vienna, Austria.
- Butsashvili M., Kamkamidze G., Metreveli D., Gamkrelidze A, Zakalashvili M., Kerashvili V., **Dolmazashvili E.**, Gamezardashvili A.
Reversal of liver damage among HCV infected persons with advanced liver disease: Two-year follow-up from the HCV elimination program, Georgia, ASM Clinical Virology Symposium, May 6-9, 2018, West Palm Beach, Florida
- **Dolmazashvili E.**, Abutidze A., Karchava M., Sharvadze L., Chkhartishvili N, Tsertsvadze T.

Regression of liver stiffness (LS) after direct acting anti-viral (DAA) therapy for hepatitis C in the country of Georgia, AASLD Liver Meeting Oct 20-24 2017, Washington DC

- **Dolmazashvili E.**, Abutidze A., Karchava M., Sharvadze L., Chkhartishvili N., Tsertsvadze T.

Regression of liver fibrosis in patients with chronic hepatitis C treated with direct acting anti-viral (DAA) therapy in the country of Georgia. 13th International Workshop on Co-infection HIV & Hepatitis, Lisbon, Portugal, June 21-23, 2017.

- **Dolmazashvili E.**, Sharvadze L., Karchava M., Gabunia P., Zhamutashvili M., Svanidze M., Abutidze A., Tsertsvadze T.

Assessment of liver fibrosis/cirrhosis using Fibroscan and FibroTest/FibroMax in patients with chronic HBV and HCV infection in Georgia. International Meeting on Emerging Diseases and Surveillance (IMED 2011), February 4-7, 2011. Vienna, Austria.

- Karchava M., Sharvadze L., **Dolmazashvili E.**, Zhamutashvili M., Iobashvili T., Chkhartishvili N., Abutidze A., Gatserelia L., Dvali N., Dzigua L., Tsertsvadze T.

Super early viral response and IL28 B genotype as the strong predictor for SVR for HCV Genotype 1 patients. International Meeting on Emerging Diseases and Surveillance (IMED 2011), February 4-7, 2011. Vienna, Austria.

- Sharvadze L., Karchava M., Gatserelia L., Chkhartishvili N., **Dolmazashvili E.**, Dvali N., Badridze N., Tsertsvadze T.

Prognostic value of IL28B for spontaneous clearance from HCV infection. International Meeting on Emerging Diseases and Surveillance (IMED 2011), February 4-7, 2011. Vienna, Austria

- Karchava M., Sharvadze L., **Dolmazashvili E.**, Abutidze A., Gatserelia L., Dvali N., Dzigua L., Tsertsvadze T.

Correlation between HIV viral load, increased fibrogenesis and HCV genotypes among HIV positive patients in Georgia. 20th European Congress of Clinical Microbiology and Infectious Diseases. 10-13 April 2010. Vienna, Austria.

Research Support

Research projects:

Project Title: Long-term health outcome among HCV patients with advanced liver fibrosis treated through HCV elimination program in Georgia

Participating Institution: Health Research Union/Clinic Neolab, Hepatology Clinic HEPA, Infectious Diseases, AIDS and Clinical Immunology Research Center, Medical Center Mrcheveli.

Donor Organization: CDC

Project Duration: 2017-2018

Role: Researcher

Project Title: Evaluation of integrated HCV treatment program in harm reduction centers of Georgia

Participating Institution: Health Research Union/Clinic Neolab, Hepatology Clinic HEPA, Infectious Diseases, AIDS and Clinical Immunology Research Center, Medical Center Mrcheveli.

Donor Organization: CDC

Project Duration: 2018

Role: Researcher

Membership

European Association for the Study of the Liver (EASL)

International Association of Surgeons, Gastroenterologists and Oncologists (IASGO)

European AIDS Clinical Society (EACS)

Georgian Hepatology Association (GHA)

Georgian Ultrasound Association

European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB)